Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy.

Oncogenesis · 2023 · PMC10113330 · PMID 37072406

Europe PMC DOI

hedged sentences

0.0001

closest p · 0.0× alpha

0.0190

boldest claim

The sentences

highly significantP < 0.0001actually significant

Survival analysis for this alteration showed that the difference between wild-type (WT) and NOTCH1 deletion patients was highly significant for both PFS (mPFS: 1.40 vs. 7.83 months; HR = 51.00, 95% CI: 4.80–540.00; P < 0.0001) and OS (mOS: 4.07 vs. 38.30 months; HR = 1 × 10 10 , 95% CI: 0-infinity; P < 0.0001) (Fig. 3G, H ).

also in 20,926 other papers

a positive trendP = 0.019actually significant

Patients who responded to treatment had a higher CIN than nonresponders, and a positive trend towards increasing CIN was observed as response improved ( P = 0.019).

also in 2,420 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.